| 1 |
Kang X, Shimada S, Miyahara H, Higuchi K, Mori M. BALB.NCT-Cpox is a unique mouse model of hereditary coproporphyria. Molecular Genetics and Metabolism Reports 2023;35:100964. [DOI: 10.1016/j.ymgmr.2023.100964] [Reference Citation Analysis]
|
| 2 |
Wang B, Bonkovsky HL, Lim JK, Balwani M. AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review. Gastroenterology 2023;164:484-91. [PMID: 36642627 DOI: 10.1053/j.gastro.2022.11.034] [Reference Citation Analysis]
|
| 3 |
Ramai D, Deliwala SS, Chandan S, Lester J, Singh J, Samanta J, di Nunzio S, Perversi F, Cappellini F, Shah A, Ghidini M, Sacco R, Facciorusso A, Giacomelli L. Reply to Lissing et al. Comment on "Ramai et al. Risk of Hepatocellular Carcinoma in Patients with Porphyria: A Systematic Review. Cancers 2022, 14, 2947". Cancers (Basel) 2023;15. [PMID: 36831530 DOI: 10.3390/cancers15041187] [Reference Citation Analysis]
|
| 4 |
Menezes PR, Trufen CEM, Lichtenstein F, Pellegrina DVDS, Reis EM, Onuki J. Transcriptome profile analysis reveals putative molecular mechanisms of 5-aminolevulinic acid toxicity. Arch Biochem Biophys 2023;738:109540. [PMID: 36746260 DOI: 10.1016/j.abb.2023.109540] [Reference Citation Analysis]
|
| 5 |
Haverkamp T, Bronisch O, Knösel T, Mogler C, Weichert W, Stauch T, Schmid C, Rummeny C, Beykirch MK, Petrides PE. Heterogeneous molecular behavior in liver tumors (HCC and CCA) of two patients with acute intermittent porphyria. J Cancer Res Clin Oncol. [DOI: 10.1007/s00432-022-04384-5] [Reference Citation Analysis]
|
| 6 |
Molina L, Zhu J, Trépo E, Bayard Q, Amaddeo G, Blanc JF, Calderaro J, Ma X, Zucman-Rossi J, Letouzé E; GENTHEP Consortium. Bi-allelic hydroxymethylbilane synthase inactivation defines a homogenous clinico-molecular subtype of hepatocellular carcinoma. J Hepatol 2022;77:1038-46. [PMID: 35636578 DOI: 10.1016/j.jhep.2022.05.018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 7 |
Fontanellas A, Avila MA. Hydroxymethylbilane synthase (aka porphobilinogen deaminase): A novel metabolic tumor suppressor gene in hepatocellular carcinoma. J Hepatol 2022;77:912-4. [PMID: 35798130 DOI: 10.1016/j.jhep.2022.06.023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 8 |
Pan K, Hu B, Wang L, Yuan J, Xu W. STUB1-SMYD2 Axis Regulates Drug Resistance in Glioma cells. J Mol Neurosci 2022. [PMID: 35939202 DOI: 10.1007/s12031-022-02051-5] [Reference Citation Analysis]
|
| 9 |
Graff E, Anderson KE, Levy C. Case Report: Lack of Response to Givosiran in a Case of ALAD Porphyria. Front Genet 2022;13:867856. [DOI: 10.3389/fgene.2022.867856] [Reference Citation Analysis]
|
| 10 |
Ramai D, Deliwala SS, Chandan S, Lester J, Singh J, Samanta J, di Nunzio S, Perversi F, Cappellini F, Shah A, Ghidini M, Sacco R, Facciorusso A, Giacomelli L. Risk of Hepatocellular Carcinoma in Patients with Porphyria: A Systematic Review. Cancers (Basel) 2022;14:2947. [PMID: 35740611 DOI: 10.3390/cancers14122947] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 11 |
Schulenburg-Brand D, Stewart F, Stein P, Rees D, Badminton M. Update on the diagnosis and management of the autosomal dominant acute hepatic porphyrias. J Clin Pathol 2022:jclinpath-2021-207647. [PMID: 35584894 DOI: 10.1136/jclinpath-2021-207647] [Reference Citation Analysis]
|
| 12 |
Jerves T, Blau N, Ferreira CR. Clinical and biochemical footprints of inherited metabolic diseases. VIII. Neoplasias. Molecular Genetics and Metabolism 2022. [DOI: 10.1016/j.ymgme.2022.03.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 13 |
Baumann K, Kauppinen R. Long-term follow-up of acute porphyria in female patients: Update of clinical outcome and life expectancy. Molecular Genetics and Metabolism Reports 2022;30:100842. [DOI: 10.1016/j.ymgmr.2022.100842] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 14 |
Lourenço CM, Anderson KE. Disorders of Haem Biosynthesis. Inborn Metabolic Diseases 2022. [DOI: 10.1007/978-3-662-63123-2_33] [Reference Citation Analysis]
|
| 15 |
Verma N, Thapa K, Kanojia N, Dureja H, Dua K. Advanced drug delivery systems targeting metabolic disorders: erythropoietic protoporphyria. Drug Delivery Systems for Metabolic Disorders 2022. [DOI: 10.1016/b978-0-323-99616-7.00024-4] [Reference Citation Analysis]
|
| 16 |
Erwin AL, Balwani M. Porphyrias in the Age of Targeted Therapies. Diagnostics (Basel) 2021;11:1795. [PMID: 34679493 DOI: 10.3390/diagnostics11101795] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 17 |
Moghe A, Anderson KE. Expanding Experience With Liver Transplantation in Acute Intermittent Porphyria. Liver Transpl 2021;27:477-8. [PMID: 33369869 DOI: 10.1002/lt.25979] [Reference Citation Analysis]
|
| 18 |
Buendía-Martínez J, Barreda-Sánchez M, Rodríguez-Peña L, Ballesta-Martínez MJ, López-González V, Sánchez-Soler MJ, Serrano-Antón AT, Pérez-Tomás ME, Gil-Ferrer R, Avilés-Plaza F, Glover-López G, Carazo-Díaz C, Guillén-Navarro E. Health impact of acute intermittent porphyria in latent and non-recurrent attacks patients. Orphanet J Rare Dis 2021;16:106. [PMID: 33639982 DOI: 10.1186/s13023-021-01742-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 19 |
Moghe A, Anderson KE. Porphyrias: Acute Manifestations. Contemporary Endocrinology 2021. [DOI: 10.1007/978-3-030-67455-7_20] [Reference Citation Analysis]
|
